Investor_Tester
14 Oct 2015
another patent Excellent rns today....but still need that FDA one to really get this rocketing! !!
millwallfan
29 Sep 2015
Re: Confused or excited ? Wow the best of both worlds if true. As per N&S post if anyone at AGM please do try and get clarification on the strategy. Regards in anticipation.
autpaxautbellum
29 Sep 2015
Re: Confused or excited ? I think the plan is to lease out the machines so that AGL can control and maintain them, with the cassettes being sold as a single use item.
niceandsimple
29 Sep 2015
Re: Confused or excited ? Maybe some could ask this at the AGM tomorrow if anyone's going
millwallfan
29 Sep 2015
Re: Confused or excited ? Hi n&s and indeed all. What I am not clear on is if Angle sell the machine for 'one off' income or charge 'per test' themselves or sell the machine and get a 'royalty' fee per test. Anyone know basis of future income ?
niceandsimple
28 Sep 2015
Re: Confused or excited ? just a thought, if just there was only 25,000 of the 200,000 uptake for our test would Medicare payments for Angle be circa $12,900,000 minus any intermediary costs?Now if 100,000 were eligible for the Medicare payment........Or am I getting it wrong againN&S
niceandsimple
28 Sep 2015
Re: Confused or excited ? Lets not forget the Medicare reimbursement of $516/test or that sadly 200,000 women per year have surgery on abnormal pelvic masses in the US aloneN&S
millwallfan
28 Sep 2015
Re: Confused or excited ? It refers to sales potential in the U.S. and Europe being in excess of £300 million so yes that is probably gross not net. However Let's assume the profit margin is near 20% for USA and Europe then add on Asia , Australasia and Africa sales in the medium term and from this single cancer type we COULD possibly have an eps approaching £1 per annum. WOW ! Share price guesses in 3 years ?????
lipsey
28 Sep 2015
Not sure if the 300 million is turnover???If its profit then you are correct??
Pyatnitsky
28 Sep 2015
Re: Confused or excited ? I suppose the real answer to that is are there other technologies that provide the same or better results more cheaply. I'm excited because ovarian cancer is hard to detect and too often reaches an advanced stage without being detected. My mother died of it as a result back in 1987. I hope other people will be spared that loss, if this technology is successful. I hope it will be priced so that it can be used as a diagnostic, like the PSA test is used for prostate cancer, although there is no mention of false positives.
millwallfan
28 Sep 2015
Confused or excited ? Our CEO in a statement today after the rns stated he considers the potential market for our system FOR OVARIAN CANCER ALONE to be c £300 million PER ANNUM.If correct then, with less than 60 million shares in issue, that would equate to £5 per share income per annum from this one source alone !! Please advise what major error of thought process I have made as I am either confused or massively excited.
autpaxautbellum
28 Sep 2015
Re: From todays EKF's RNS Good spot Nice.Should be good for Angle but EKF need to get sorted on heir reorganisation and the collaboration will hopefully kick on more quickly.
niceandsimple
28 Sep 2015
From todays EKF's RNS "PointMan................ Following some technical issues earlier in the year, we are now finalising the verification and validation process for the PointMan amplification technology with the intention of completing the CE Marking process in H2. In addition the partnerships with ANGLE, Gilupi and MGH continue to progress. The exquisite sensitivity of the PointMan technology enables us to detect three copies of a mutant gene in a standard blood draw, which will lead to a reduction in repeat tissue biopsies for cancer patients globally......."N&S
millwallfan
23 Sep 2015
Re: Sales have began N&S. Good find. Let's hope things start moving apace and ANG get a strong foothold and international credibility ahead of all competition. USA approval obviously critical but the emerging markets and population densities of the Far East ( China and India) will also be key targets I would imagine. I wonder what the profit margin per machine is and the size of the potential world market eg I do not imagine every hospital would need one - just cancer specialists - but would they require more than one machine? Interesting times ahead as a stand alone company OR potential take over target for a major pharma who may want to retain the technology and then charge 'per test' from a chain of laboratories !
niceandsimple
22 Sep 2015
Sales have began [link]
